MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, " Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening", will also appear in the journal's March 14, 2024 print issue. The 20,000-participant BLUE-C study was designed to determine the performance characteristics of Exact Sciences’ ...

Exact Sciences (EXAS) closed the last trading session at $61.46, gaining 0.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $95.53 indicates a 55.4% upside potential.The mean estimate comprises 17 short-term price targets with a standard deviation of $15.39. While the lowest estimate of $73 indicates an 18.8% increase from the current price level, the most optimistic analyst expe ...

Underdogs stocks carry almost universal appeal. It’s one thing to go with the rest of the crowd. It’s quite another to take your time to find some diamonds in the rough that could yield considerable returns.Basically, these hidden gems represent the universal desire to pioneer a particular accomplishment. For example, we all remember who first stepped foot on the moon. We don’t really discuss who was the last person to do it, as monumental of a triumph that it is.Now, that’s not to say that you can’t extrac ...

Key PointsNancy Pelosi bought Palo Alto Networks before and after the 27% stock price implosion. Victoria Spartz is buying into Simon Property Group's long-term appeal. Kevin Hearn is an active investor; he bought JPM and sold these two stocks analysts are bullish on. 5 stocks we like better than Palo Alto NetworksThe STOCK Act of 2012 was supposed to halt insider trading by members of Congress, but let’s be honest. The STOCK Act can’t really stop Congresspeople from trading on insider knowledge; they’re in ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. TD Cowen 44th Annual Health Care Conference, Boston Fireside chat on Monday, March 4, 2024 at 1:30 p.m. ET The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com. About Exact Sciences ...

Exact Sciences Corporation (EXAS) reported a net loss of 27 cents per share for fourth-quarter 2023, a significant improvement from the year-ago loss of 72 cents per share as well as the Zacks Consensus Estimate of a loss of 53 cents.Full-year net loss was $1.13 per share, narrower than the Zacks Consensus Estimate of a loss of $1.39. It also marked an improvement from a loss of $3.54 per share loss incurred in 2022.Revenues in DetailFourth-quarter consolidated revenues were $646.9 million, up 17% (up 18% o ...

Exact Sciences Corporation (NASDAQ:EXAS) Q4 2023 Earnings Call Transcript February 21, 2024 5:00 PM ET Company Participants Nate Harrill - VP of IR Kevin Conroy - Chairman and CEO Jeff Elliott - CFO Everett Cunningham - CCO Brian Baranick - GM, Precision Oncology Conference Call Participants Brandon Couillard - Jefferies Catherine Schulte - Baird Doug Schenkel - Wolfe Research Dan Brennan - Cowen Vijay Kumar - Evercore ISI Dan Arias - Stifel Andrew Brackmann - William Blair Matt Sykes - Goldman Sachs Patric ...

We aim to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Fourth-quarter 2023 earnings call February 21, 2024 EXACT SCIENCES 1 Safe harbor and non-GAAP disclosures This pre ...

Exact Sciences (EXAS) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 49.06%. A quarter ago, it was expected that this molecular diagnostics company would post a loss of $0.49 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35092 _____________________________________________________________________________ EXACT SCIENCES COR ...